Profile
Dirk G.
Brockstedt is an Independent Director at Helix BioPharma Corp.
starting in 2026.
Dr. Brockstedt is an Executive-in-Residence at ShangPharma Innovation, Inc. Former roles include Chief Scientific Officer at Rapt Therapeutics, Inc. from 2019 to 2026, Executive Vice President-Research & Development at Aduro BioTech, Inc. from 2016 to 2017, Director-Research at Anza Therapeutics, Inc. from 2007 to 2009, Immunology Director at Cerus Corp.
from 2002 to 2007, and Senior Research Scientist at Aventis, Inc. Education includes graduate and doctorate degrees from the University of Kiel.
Dirk Brockstedt active positions
| Companies | Position | Start |
|---|---|---|
| HELIX BIOPHARMA CORP. | Director/Board Member | 27/09/2026 |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation invests in companies located in the United States. The firm targets companies operating in the fields of healthcare sector. It provides financing for seed to early stage capital requirements. | Consultant / Advisor | - |
Former positions of Dirk Brockstedt
| Companies | Position | End |
|---|---|---|
| RAPT THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 02/03/2026 |
| CHINOOK THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 30/11/2017 |
Anza Therapeutics, Inc.
Anza Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops therapeutic vaccines for cancer and infectious diseases | Chief Tech/Sci/R&D Officer | 31/12/2008 |
| CERUS CORPORATION | Corporate Officer/Principal | 31/12/2006 |
Aventis, Inc.
Aventis, Inc. MiscellaneousMiscellaneous Functions as an investment holding company | Corporate Officer/Principal | - |
Education of Dirk Brockstedt
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
Cerus Corp.
Cerus Corp. Medical SpecialtiesHealth Technology Develops and commercializes the INTERCEPT Blood System for platelets and plasma | Health Technology |
Helix BioPharma Corp.
Helix BioPharma Corp. Pharmaceuticals: MajorHealth Technology Develops drugs for the prevention and treatment of cancer | Health Technology |
Aventis, Inc.
Aventis, Inc. MiscellaneousMiscellaneous Functions as an investment holding company | Miscellaneous |
Aduro BioTech, Inc.
Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company, which focuses on the development of technology platforms for cancer | Health Technology |
University of Kiel
University of Kiel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anza Therapeutics, Inc.
Anza Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops therapeutic vaccines for cancer and infectious diseases | Health Technology |
Rapt Therapeutics, Inc.
Rapt Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes oral small molecule therapies for patients | Health Technology |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation invests in companies located in the United States. The firm targets companies operating in the fields of healthcare sector. It provides financing for seed to early stage capital requirements. | Finance |
- Stock Market
- Insiders
- Dirk Brockstedt
















